Inclusion completed

A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia

Cancer type: Leukemia

Phase: I/II

Principal Investigator: Gjertsen Bjørn Tore

Country: NO

Keywords: Norway, Bergen

Status: Inclusion completed

Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01725204